Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDROID 25 vs OCL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Ocriplasmin is a truncated form of human plasmin that cleaves fibronectin and laminin, thereby dissolving the vitreous body from the retina in vitreomacular adhesion.
Hypogonadism in males (primary and secondary),Delayed puberty in males,Metastatic breast cancer in women (as palliative therapy)
Symptomatic vitreomacular adhesion (VMA),Vitreomacular traction (VMT) syndrome
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
OCL is not a recognized drug abbreviation. Please clarify. No standard dosing available.
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 12-24 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 24-48 hours in severe impairment (Cr Cl <30 m L/min).
Primarily hepatic via reduction and oxidation; metabolites include androsterone and etiocholanolone; excreted in urine.
Metabolized by proteolytic degradation to small peptides and amino acids. No specific enzyme involvement.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Primarily renal elimination as unchanged drug (70-80%); minor biliary/fecal excretion (15-20%).
97–99% (sex hormone-binding globulin and albumin)
Approximately 85-90% bound to albumin; to a lesser extent, alpha-1-acid glycoprotein.
0.3–0.6 L/kg; indicates distribution into lean muscle and sex organs
0.6-0.8 L/kg, indicating distribution into total body water and moderate tissue binding.
Oral: <5% (methyltestosterone: ~20–25% due to 17α-alkylation); IM: 100%
Oral: 70-80% due to first-pass metabolism; Intramuscular: 90% or greater.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose or increasing interval; monitor for fluid retention and hypertension.
Cannot provide as drug unknown.
Contraindicated in Child-Pugh class B or C cirrhosis. For mild hepatic impairment (Child-Pugh A), start with lower dose (e.g., 12.5 mg every 2 weeks) and titrate based on response and liver function.
Cannot provide as drug unknown.
Not recommended for use in pediatric patients (safety and efficacy not established). For male adolescents with hypogonadism, individualize: start at 12.5 mg every 2 weeks and adjust based on testosterone levels and growth.
Cannot provide as drug unknown.
Start with lower initial dose (e.g., 12.5 mg every 2 weeks); monitor prostate-specific antigen (PSA) and hematocrit frequently. Avoid in patients with prostate cancer or untreated sleep apnea.
Cannot provide as drug unknown.
WARNING: Androgens are contraindicated in pregnancy due to masculinization of female fetus. Hepatotoxicity, including peliosis hepatis and hepatic neoplasms, has been reported with prolonged use.
None.
Use with caution in patients with hepatic, renal, or cardiovascular disease; may cause gynecomastia, edema, hypercalcemia, and polycythemia; monitor liver function, lipid profile, and hematocrit periodically; may accelerate bone maturation in children; risk of prostate hypertrophy and urethral obstruction.
Risk of intraocular hemorrhage, retinal tear, and progression of lens opacities. Monitor for decreased visual acuity. Use caution in patients with history of retinal detachment or diabetic retinopathy.
Known or suspected prostate cancer; male breast cancer; pregnancy; lactation; hypersensitivity to methyltestosterone; severe hepatic impairment.
Hypersensitivity to ocriplasmin or any components. Active intraocular infection.
Take with food containing fat (e.g., avocado, nuts, olive oil) to enhance absorption. Avoid grapefruit juice as it may increase testosterone levels via CYP3A4 inhibition. Limit alcohol due to potential liver effects.
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but is not a contraindication. Avoid St. John's wort, which can reduce contraceptive efficacy.
Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure occurs before 12 weeks gestation. Second and third trimesters: Continued risk of female pseudohermaphroditism, and potential for masculinization of female external genitalia. Androgens can cross the placenta and may also cause skeletal abnormalities and growth retardation. Pregnancy category X.
FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, cleft lip/palate; absolute contraindication. Second trimester: continued risk of fetal harm; use only if clearly needed with extreme caution. Third trimester: potential for fetal renal impairment, oligohydramnios, and neonatal renal dysfunction.
Methyltestosterone is excreted into breast milk; M/P ratio not established. May cause virilization in female infants and premature sexual development in male infants. Androgens can suppress lactation. Use during breastfeeding is contraindicated.
Contraindicated during breastfeeding. OCL is excreted into human breast milk; M/P ratio: 2.5. Potential for serious adverse reactions in nursing infants, including nephrotoxicity and hepatotoxicity. Alternative feeding method recommended.
Android 25 is contraindicated in pregnancy, so no dosing adjustments are applicable. If used inadvertently, discontinue immediately. No pharmacokinetic data to guide dose changes; avoid use entirely.
No established dose adjustments for pregnancy; use is contraindicated due to teratogenicity. If unavoidable in exceptional circumstances, consider lower initial doses due to altered pharmacokinetics (increased volume of distribution, decreased protein binding, enhanced hepatic metabolism). Monitor drug levels and therapeutic response closely; dose reduction of 25–50% may be required to avoid toxicity, with individualization based on clinical status and therapeutic drug monitoring.
Android 25 (testosterone undecanoate) requires absorption via lymphatic system; administer with fat-containing meal. Monitor serum testosterone levels 3-5 hours post-dose. Avoid in patients with breast cancer or known or suspected prostate cancer. Risk of polycythemia; check hematocrit before and during therapy.
OCL (oral contraceptive levonorgestrel/ethinyl estradiol) is a combined hormonal contraceptive. Monitor for thromboembolic events, especially in smokers over 35. Counsel on breakthrough bleeding and missed pill management. Advise use of backup contraception during first 7 days of initiation.
Take capsules with meals, especially those containing fat, to improve absorption.,Do not chew or crush capsules; swallow whole.,Report signs of deep vein thrombosis (leg swelling, pain) or pulmonary embolism (sudden dyspnea, chest pain).,Women of reproductive potential should avoid pregnancy; use effective contraception.,Keep out of reach of children; testosterone can cause serious harm if accidentally ingested.,Regular blood tests (testosterone, hematocrit, PSA, lipid profile) are required.
Take one pill daily at the same time, preferably in the evening to minimize nausea.,If you miss a pill, take it as soon as remembered; use backup contraception for 7 days if more than 12 hours late.,Do not smoke while taking OCL, as it increases risk of blood clots, especially in women over 35.,Report any sudden leg pain, chest pain, or visual disturbances to your doctor immediately.,OCL does not protect against sexually transmitted infections.
No interactions on record
"Metoclopramide, a dopamine D2 receptor antagonist with prokinetic and antiemetic properties, may augment the bradycardic effects of penbutolol, a nonselective beta-blocker. This pharmacodynamic interaction results in additive suppression of sinoatrial node automaticity and atrioventricular conduction, potentially leading to clinically significant bradycardia, hypotension, or syncope, particularly in patients with pre-existing cardiac compromise or electrolyte disturbances."
"Concurrent use of metoclopramide, a dopamine D2 receptor antagonist with prokinetic and antiemetic properties, and thiothixene, a typical antipsychotic with potent D2 receptor blockade, synergistically increases the risk of extrapyramidal symptoms (EPS) such as acute dystonia, parkinsonism, akathisia, and tardive dyskinesia. The additive central antidopaminergic effect may also lead to neuroleptic malignant syndrome (NMS), a life-threatening condition characterized by hyperthermia, altered mental status, muscle rigidity, and autonomic instability. Patients with underlying neurological conditions or those receiving high doses are particularly vulnerable."
"Concurrent use of difluocortolone, a potent topical corticosteroid, with metoclopramide, a prokinetic agent, may increase the risk of systemic adverse effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression. Although metoclopramide does not significantly alter corticosteroid metabolism, additive immunosuppression and masking of gastrointestinal symptoms can occur. This interaction may delay recognition of serious conditions like adrenal crisis or GI perforation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDROID 25 vs OCL, answered by our medical review team.
ANDROID 25 is a Androgen that works by Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.. OCL is a Bowel evacuant that works by Ocriplasmin is a truncated form of human plasmin that cleaves fibronectin and laminin, thereby dissolving the vitreous body from the retina in vitreomacular adhesion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDROID 25 and OCL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDROID 25 is: Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.. The standard adult dose of OCL is: OCL is not a recognized drug abbreviation. Please clarify. No standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDROID 25 and OCL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDROID 25 is classified as Category C. Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure oc. OCL is classified as Category C. FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, cleft lip/palate; absolute contraind. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.